The deal between Albumedix and Eleven Biotherapeutics was completed on 4 December 2015. The terms of the agreement are not disclosed but under the agreement, Albumedix will pay Eleven an upfront fee as well as a share of commercialisation income. Things look a bit rough here, but that sounds like a lump sum of cash and a future revenue stream. I guess it depends what Albumedix does with it.
News 
Market Data 
Discover 
AI
